Congestive heart failure (CHF) is an increasing problem for healthcare systems in all developed countries. The prevalence is increasing partly due to ageing of the population, but also due to improved survival from acute cardiac disease such as myocardial infarction. Advances in diagnostic techniques and better understanding of the pathophysiology offer many opportunities for substantial improvement in the management of CHF. This article reviews the current epidemiology of CHF and the related diagnostic issues.
Introduction
The developed world is in the midst of an epidemic of congestive heart failure (CHF). Much of the increase in the burden of CHF relates to the powerful demographic forces being played out in modern populations -a shrinking young population and a rapid expansion in the numbers of the elderly and very elderly. Over the previous four decades, there has been a 50% rise in the number of people over the age of 65 in the UK, and a threefold increase in the number of people living to at least 85 years. 1 As CHF is chiefly a disease of middle or later life, such a 'greying' of the population has a huge impact. Steadily improving survival from myocardial infarction (MI) also translates into a larger number of people with damaged hearts, a substantial proportion of which are likely to develop CHF in due course. 2, 3 Modern drug therapy improves the prognosis of CHF, and consequently increases the number of people living with the condition. It is therefore perhaps not surprising that many countries have reported a massive increase in health service activity related to CHF since the 1970s. [3] [4] [5] Advances in diagnostic techniques and better understanding of the pathophysiology of CHF offer many opportunities for substantial improvement in its management. All healthcare systems face the challenge of facilitating the rapid adoption of best practice. Codification of best practice in national and international guidelines, coupled with clinical audit, may lead to more consistent and evidence-based care. Considerable and sustained effort is necessary if we are to deliver humane, effective and efficient care to the increasing number of patients with CHF. Two of the key challenges are improving access to echocardiography, and increasing the use of drugs known to improve prognosis for patients with underlying left ventricular (LV) systolic dysfunction (angiotensin-converting enzyme (ACE) inhibitors and β-blockers).
How common is congestive heart failure (CHF)?
This question is difficult to answer.There are very few population-based CHF registers. Relying on routinely collected data, such as death certification, is problematic because not every patient with CHF dies from that condition, and, if they do, CHF may not be recorded. Routine hospital coding may not only be unreliable, but only applies to those patients who have been admitted to hospital. Estimates based on routine general practice records are also unreliable. In many cases, the diagnosis of CHF has not been objectively verified. Several studies suggest that only 33-50% of patients with a diagnosis of CHF in primary care have this diagnosis confirmed on further assessment. [6] [7] [8] [9] For many years, the only source of reliable epidemiological data on CHF was the Framingham Heart Study. This cohort study was set up in one small semi-urban area of Massachusetts in 1948, with the cohort being re-examined every two years.A scoring system based on symptoms, clinical signs and investigations such as a chest radiograph and spirometry was used to diagnose CHF. 10 This definition is not used in modern clinical practice, although attempts to modernise the scoring system have been made. 11 The majority of recent population-based studies of CHF have either employed expert panels to adjudicate on the clinical history, examination, and the results of investigations (including echocardiography), 6 or have concentrated on describing cardiac structure and function (such as LV systolic dysfunction) in the population.
The literature on the epidemiology of CHF is confined to studies in developed countries. Small case series have been published from several developing countries, and are reviewed elsewhere. 12 Rheumatic fever practically vanished from developed countries in the early part of the 20th Century, but remains a major problem in many developing countries, particularly in Africa and Asia. Hypertension on its own is reported as a common cause of CHF in some populations, particularly those of African origin. Chagas disease is still a common cause of CHF in South America. In developed countries, the single most common cause of CHF is coronary artery disease, often The 'Westernisation' of lifestyle in many developing countries, coupled with improving life expectancy, has led to a steadily increasing prevalence of coronary heart disease in such populations. It is likely that the total number of people in the world with CHF will increase steadily during this century -with a rise in both the developed and developing world. Coronary heart disease will account for a large share of this.
The prevalence of CHF
In developed countries, about 1-2% of the general population have CHF. 4 Prevalence rises sharply with age and is more common in men than in women at all ages. 4, 13, 14 Epidemiological studies in the Netherlands suggests a prevalence of CHF of 3.9% in the general population aged 55-95 years. 15 Estimates from a survey in Olmsted County, Minnesota, USA reported the prevalence of 2.2% in residents aged 45 years or above. 16 A study in Scotland reported definite LV systolic dysfunction in 2.9% of men and women aged 25-74 years, half of whom had symptoms compatible with CHF 17 ( Table 1 ).
The incidence of CHF
New cases of CHF arise at a rate of 1-5 cases per 1,000 population annually with a steep rise with age. 4, 13 In the Hillingdon Heart Failure Study in West London, UK, the incidence of CHF was 0.02 cases per 1,000 per annum in the 25-34 age group, increasing to 11.6 in those 85 years and older ( Figure 1 ). 6 There are few reliable estimates of the secular trend in the incidence of CHF. The Framingham Heart Study reported no change in incidence for men between the 1950s and 1990s, in contrast to a 30-40% decline in women. 18 No change in incidence was reported from Minnesota, USA, between 1981 and 1991. 19
Survival from CHF
The mortality among CHF patients continues to be high -although it has improved over time.The Framingham Heart Study reported that the median survival after diagnosis was 1.7 years and 3.2 years for men and women, respectively, and that mortality rates were 4-8 times that of the age-matched general US population. 20 A 12% improvement in survival per decade during 1950 to 1999 for both sexes was also reported for this cohort. 18 A recent UK population-based study reported a survival of 70% at six months from the time of diagnosis, 62% at 12 months and 57% by 18 months (Figure 2 ). 21 Patients admitted to hospital with CHF for the first time have a mortality rate higher than that of many cancers, such as breast, uterus, bladder and prostate. 22 The mortality of CHF in epidemiological studies is higher than that reported from many clinical trials of drug therapy for CHF, [23] [24] [25] survived the early 'high-risk' period, are more compliant with therapy, 26 are followed and managed more closely and appear to be in better health than the average patient with CHF. The median age of CHF patients in clinical trials is about 62 years of age, whereas community dwelling CHF patients have a median age of about 76 years 27, 28 and often have considerable co-morbidity. Many factors have been reported to be associated with increased mortality in CHF patients. Several demographic and clinical features appear to be consistently associated with a poor prognosis, despite differences in the study populations: older age, more severe symptoms, lower blood pressure, worse LV systolic function, poorer exercise tolerance, and poorer renal function. 15, 21, 29 Several studies have reported that women with CHF have a lower mortality rate than men. This may be due to a higher proportion of false-positive diagnosis in women, 30 or more likely, to a true difference in the characteristics of the syndrome in women -a higher proportion of cases due to isolated diastolic abnormalities of the left ventricle, rather than systolic dysfunction.
Racial differences in the survival rates of CHF have also been documented. In the USA, mortality from CHF among black men is estimated to be 1.8 times higher than that among white men, and about 2.4 times higher in black women compared with white women. 31, 32 Several explanations have been invoked, including differences in the aetiology, severity, or management of CHF, co-morbidities and also, perhaps, socio-economic factors.
Morbidity due to CHF CHF causes considerable morbidity, with a greater impact on a patient's quality of life than many other chronic conditions. 33 Many CHF patients are elderly and may suffer from other chronic medical conditions, including lung disease, diabetes, osteoarthritis, or dementia.The inability to undertake even gentle exertion may have a huge impact on the activities of daily living, with serious consequences for the patient and their carers.
Healthcare activity related to CHF
Hospitalisation is common in patients with CHF, either due to decompensation of the CHF, or other medical conditions. [34] [35] [36] [37] About 5% of all adult general medical admissions are due to CHF. 38, 39 The average length of hospital stay for these patients in the UK was about 11.4 days on an acute medical ward and 28.5 days on a geriatric ward in 1990. 38 In 2000-2001, it was estimated to be over 13 days, three times longer than the average length of stay for all patients. 40 Similar data have been reported from several other developed countries. 4, 32, 37, 41, 42 Hospital admissions for CHF in the UK are projected to rise by 50% over the next 25 years. 43 In developed countries, the management of CHF consumes about 1-2% of the total healthcare budget annually. 44, 45 The total estimated cost of CHF to the NHS in the UK is about £625 million per annum. About two thirds of this expenditure relates to the cost of hospital admissions, 36, 40, 46 with primary care activity accounting for 17% ( Figure 3 ). 40 In the UK, a patient with CHF consults the primary care team 11-13 times each year. 47
Diagnostic issues
CHF is a complex syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the heart to function as a pump. The syndrome is characterised by symptoms such as breathlessness and fatigue, and signs such as fluid retention. Unfortunately, there is no single diagnostic test for CHF, and diagnosis relies on clinical judgement based on a combination of history, physical examination and appropriate investigations. A full clinical evaluation is more than just stating whether the syndrome is present or not -consideration needs to be given to the underlying abnormality of the heart, the severity of the syndrome, the aetiology, precipitating and exacerbating factors, identification of concomitant disease relevant to the management, and an estimation of prognosis. Every effort should be made to exclude other disorders that may present in a similar manner (such as chronic lung disease, obesity, venous insufficiency in the lower limbs, intrinsic hepatic or renal disease, severe anaemia or thyroid disease).
International guidelines have been published on the diagnosis (and management) of CHF. 48, 49 Objective confirmation of a clinical suspicion of CHF is strongly recommended, with documentation of the structure and function of the heart being central to a full evaluation of the patient. Transthoracic echocardiography is widely held to be the most practical and useful method of imaging the heart, although other techniques, such as cardiac magnetic resonance imaging, also have much to offer. Echocardiography (including Doppler) examination of the heart can provide much useful information on the structure and systolic function of the left ventricle, the size of the atria, and valvular structure and function.There is much controversy, however, about the ability of this investigation to positively confirm a diagnosis of CHF due to isolated LV diastolic dysfunction ('diastolic CHF').This diagnosis can be confirmed by invasive investigation at cardiac catheterisation, but in practice the diagnosis is more usually based on the finding of typical symptoms and Figure 4 for the diagnosis of CHF. 50 In healthcare systems in which access to transthoracic echocardiography is not as restrained as in the UK, the clinician may be able to include echocardiography as a first-line investigation in all patients who present with breathlessness or fluid retention. The proportion of normal echocardiographic examinations is likely to be very high (depending on the nature of the clinician's practice) and in the UK the 12-lead resting ECG and the plasma concentration of B-type Natriuretic Peptides (BNP) (or NT-proBNP) has been proposed to ensure a more efficient use of echocardiography -if both of those tests are completely normal then CHF is very unlikely.
The electrocardiogram (ECG)
Most guidelines recommend that a 12-lead ECG 51, 52 be performed, as it provides information that may be suggestive of the causal or contributory factors to a patient's CHF. Anterior Q-waves, or left bundle branch block, may be associated with LV dysfunction. Arrhythmias such as atrial fibrillation may aggravate or precipitate CHF, and will also complicate management decisions.The value of the ECG is in its negative predictive value -i.e. if it is completely normal then CHF is unlikely.
However, the positive predictive value of a resting 12-lead ECG reduces with advancing age.A prospective study in Dundee, UK, evaluated the measurement of plasma BNP concentration and the ECG in 299 patients with an average age of 79 years attending a Day Hospital.The electrocardiogram was highly sensitive (97%) in excluding LV systolic dysfunction but had a specificity of only 50%. 53
B-type Natriuretic Peptides (BNP or NT-proBNP)
BNP is produced by myocardial tissue in response to cardiac stretch or strain. It promotes diuresis, vasodilation and natriuresis and acts as an antagonist to the renin-angiotensin-aldosterone-system. The circulating concentration of the active hormone (BNP) and the co-secreted inactive peptide (NT-proBNP) is raised in CHF. 54, 55 The measurement of this peptide in patients presenting with new symptoms shows considerable promise in clinical practice, particularly as rapid laboratory and point-of-care testing is now commercially available. 56 The area under the receiver operating characteristics curve for BNP is above 0.90 in both the clinic and emergency care setting. 57, 58 It is possible to choose a plasma concentration below which the negative predictive value is very high and BNP can then be used as a 'rule-out' test for CHF in patients with new symptoms, as suggested by the guidelines on diagnosis of CHF from the European Society of Cardiology and the National Institute of Clinical Excellence in England. 48, 50 The diagnostic value for patients with a historical diagnosis of CHF, or asymptomatic cardiac dysfunction, is somewhat poorer, owing to the plasma concentrations being lower and overlapping more with 'normals'. 54
Chest radiography
Historically, the chest radiograph was relied upon to confirm a diagnosis of CHF. Pulmonary venous blood diversion, interstitial or alveolar pulmonary oedema, and cardiomegaly were considered useful signs. Although undoubtedly useful in uncovering some pulmonary disease (such as pneumonia and neoplasm), the value in detecting CHF may be lower than is believed by many. A recent review reported that cardiomegaly on the chest radiograph has a sensitivity of 51% and a specificity of 79% in detecting a decreased ejection fraction, while upper lobe blood diversion carried a sensitivity of only 37% and a specificity of 67%. 59 Challenges to improving CHF management Improving access to echocardiography The IMPROVEMENT Study (Improvement Programme in Evaluation and Management) surveyed primary care physicians' knowledge and perception of CHF management in 15 European countries. Only about 45% of primary care physicians reported that they would usually request an echocardiogram in the investigation of patients with suspected CHF. 60 Access to echocardiography for non-specialist clinicians is poor in many European countries and is working at near full capacity: the Euro-HF Survey across six European countries found that only 5% (Netherlands) to 37% (UK) of general practitioners had direct access to echocardiography. 61 Even when patients are admitted to hospital, echocardiography is often not performed as part of the evaluation of the patient with CHF. The Euro-Heart Heart Failure Survey reported that, whereas more than 90% of patients were investigated with an ECG, chest radiography and blood biochemistry, only 66% had ever had an echocardiogram. Substantial variations between study countries were apparent, with patients in Northern European countries such as the UK HEART FAILURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM (56%), Sweden (68%) and Denmark (41%) being less likely to be investigated using echocardiography than their Western European counterparts -France (93%), Netherlands (94%) and Germany (88%). It has been suggested that such variation might reflect differences in the proportion of patients with CHF under the care of a specialist rather than generalist. 62 Wider, and more rapid, access to echocardiography is key to improving diagnostic services for patients with suspected CHF. The method of delivering better access is likely to vary depending on local resources and constraints. Undoubtedly, such access will result in more appropriate decisionmaking by clinicians, 63 particularly if supported by an integrated approach across the local healthcare community. It has also been suggested that opening access to such services may reduce secondary care workloads, and may be a more costeffective use of overall healthcare resources. 64, 65 Increasing treatment with proven therapies There is consensus that patients with heart failure due to left ventricular systolic dysfunction should be treated with ACE inhibitors (ACE-I) and β-blockers, provided there is no overwhelming contraindication. Many reports continue to suggest that the use of such life-prolonging therapy is suboptimal -albeit with some improvement in recent years. 66, 67 The Euro-Heart Heart Failure survey programme 66 suggests that, even in hospital-based care, only 62% of patients were prescribed ACE-Is, and 37% β-blockers.The average daily dose of ACE-Is and β-blockers was well below the recommended target dose. Only 17% of the enrolled patients were treated with a diuretic,ACE-I and βblocker combination. For perhaps rather obvious reasons, patients were almost three times as likely to receive a β-blocker if they were admitted to a cardiology ward rather than a general ward, or if they had a diagnosis of ischaemic heart disease. Men were more likely to be prescribed ACE-Is than women, while patients aged over 70 were less likely to be prescribed either ACE-Is or β-blockers than their younger counterparts.
It is generally held that clinical guidelines, treatment algorithms, and clinical audit will speed up the adoption of evidence-based practice. Such encouragements to good practice may have to be coupled with penalties for failing to deliver on targets if we are to see rapid improvements in care for patients with heart failure. 
